Posters

2016



PP01
|
ACCURACY OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING USING 1.5 TESLA AND ULTRASOUND – GUIDED TRANSRECTAL COGNITIVE APPROACH

P. Contreras, L. Blas, H. Rios Pita, M. Mieggi, E. Mondelo, E. Rojas Bilbao
Hospital Alemάn, Buenos Aires, Argentina

PP02 | ANALGESIC EFFICACY AND MODE OF ACTION OF ELECTROACUPUNCTURE IN A RAT MODEL OF PROSTATE CANCER-INDUCED BONE PAIN
S. Kim
School of Korean Medicine, Pusan National University, Yangsan, Korea Republic

PP03 | CHOOSING ACTIVE SURVEILLANCE VERSUS DEFINITIVE TREATMENT FOR PROSTATE CANCER: WHAT IS THE VALUE OF AN APPROACH COMBINING MULTIPARAMETRIC MRI (MPMRI) AND TRUS-GUIDED BIOPSY?
R. T. Gupta, J. N. Holtz, R. K. Silverman, K. J. Tay, T. J. Polascik
Duke University Medical Center, Durham, North Carolina, USA

PP04 | CORRELATION BETWEEN PROSTATE CANCER LOCALIZATION IN MULTIPAREMETRIC MAGNETIC RESONANCE IMAGING AND RADICAL PROSTATECTOMY HISTOPATHOLOGY
P. Contreras, L. Blas, H. Rios Pita, M. Mieggi, E. Mondelo, A.M. Chirife
Hospital Alemάn, Buenos Aires, Argentina

PP05 | CURRENT KNOWLEDGE, ATTITUDE, AND PRACTICE PATTERNS AMONG UROLOGISTS REGARDING PROSTATE MAGNETIC RESONANCE IMAGING (MRI) AND MR TARGETED BIOPSY
A. Muthigi1, A. Sidana1, A. K. George1, M. Kongnyuy1, S. Valayil1, M. Maruf1, K. Hammerich1, L. Krane1, B. J. Wood2, P. A. Pinto1
1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
2 Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland

PP06 | DOES THE ADDITION OF STANDARD SYSTEMATIC BIOPSIES TO TARGET PROSTATE BIOPSIES INFLUENCE TREATMENT CHOICES FOR PATIENTS AND CLINICIANS?
W. C. Behl1, J. Yu2, A. S. Fulcher2, S. G. Winks2, M. A. Turner2, A. L. Ware2, M. Anscher3, L. Hampton4
1 VCU School of Medicine, Richmond, USA
2 VCU Medical Center, Dept of Radiology, Richmond, USA
3 VCU Medical Center, Dept of Radiation Oncology, Richmond, USA
4 VCU Medical Center, Dept of Urology, Richmond, USA

PP07 | WITHDRAWN

PP08 | HIGH RESOLUTION SOFT X-RAY MICROPROBE (HRSXRM) FOR ANALYZING ONCOGENIC CELLULAR TRANSFORMATION IN KIDNEYS AND PROSTATES
P. Dikedi
Veritas University, Abuja, FCT, Nigeria

PP09 | INTRA-PROSTATIC EXTENT AND LOCATION OF CANCER: THERAPEUTIC IMPLICATIONS
A. Shtricker, L. Schreiber, A. A. Sidi, A. Tsivian
Departments of Urologic Surgery and Pathology, The Edith Wolfson Medical Center, Holon, Sackler School of Medicine, Tel Aviv University, Israel

PP10 | LOW SUSPICION LESIONS ON MULTIPARAMETRIC MRI: WHEN SHOULD THESE LESIONS BE BIOPSIED?
M. Maruf1, A. Sidana1, A. George1, M. Kongnyuy1, M. Kadakia1, A. Muthigi1, K. Hammerich1, D. Su1, M. Merino2, P. Choyke3, B. Turkbey3, B. Wood4, P. Pinto1
1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA
2 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, USA
3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, USA
4 Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, USA

PP11 | MRI FUSION PROSTATE BIOPSY OUTPERFORMS 12-CORE SYSTEMATIC PROSTATE BIOPSY IN PATIENTS WITH PRIOR NEGATIVE BIOPSY: A MULTI-INSTITUTIONAL ANALYSIS
A. Sidana1, J. Gordetsky2,3, J. Nix3, B. Turkbey4, P. Choyke4, B. Wood5, P. Pinto1, M. Watson6, M. Mahir1, A. George1, M. Merino7, M. M. Siddiqui1, S. Rais-Bahrami1, A. Rastinehad8, S. Vourganti9
1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
2 Department of Pathology, University of Alabama, Birmingham, AL, USA
3 Department of Urology, University of Alabama, Birmingham, AL, USA
4 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, USA
5 Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, USA
6 Michigan State University College of Osteopathic Medicine, MI, USA
7 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, USA
8 Icahn School of Medicine at Mount Sinai, NY, USA
9 SUNY Upstate Medical University, Syracuse, NY, USA.

PP12 | MRI TUMOR CONTACT LENGTH WITH PROSTATE CAPSULE COMPARED TO PARTIN TABLES IN THE PREDICTION OF ADVERSE PATHOLOGICAL OUTCOMES IN PROSTATE CANCER
M. Kongnyuy, P. L. Choyke, B. J. Wood, P. A. Pinto, B. Turkbey, A. Sidana, A. K. George, A. Muthigi, A. Iyer, R. Ho, T. P. Frye, D. Su, M. J. Merino
National Cancer Institute, NIH, Bethesda, USA

PP13 | MRI/TRUS FUSION-GUIDED BIOPSY TECHNIQUE: CHARACTERIZATION OF THE LEARNING CURVE IN PROSTATE PHANTOM MODELS
A. Muthigi1, A. K. George1, M. Kongnyuy1, M. Maruf1, D. Su1, S. Valayil1, P. Yan3, A. Sidana1, T. P. Frye1, H. Narayanan3, J. Thai3, B. Turkbey2, P. L. Choyke2, B. J. Wood3, P. A. Pinto1
1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
2 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
3 Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland

PP14 | NEW PROGNOSTIC GRADE GROUP (PGG) PROSTATE CANCER GRADING SYSTEM: CAN MULTIPARAMETRIC MRI (MPMRI) AND TRUS-GUIDED BIOPSY ACCURATELY SEPARATE PATIENTS WITH LOW, INTERMEDIATE AND HIGH GRADE CANCER?
J. N. Holtz, R. K. Silverman, K. J. Tay, T. J. Polascik, R. T. Gupta
Duke University Medical Center, Durham, North Carolina, USA

PP15 | PROGNOSTIC SIGNIFICANCE OF GLEASON GRADE 5 IN PROSTATE CANCER WITH GLEASON SCORE 8
A. Sivaraman, R. Sanchez-Salas, E. Barret, E. Espinos Linares, J. I. Perez-Reggeti, M. Galino, F. Rozet, X. Cathelineau
Institut Mutualiste Montsouris, Paris, France

PP16 | RISK ASSESSMENT FOR UNDERTREATMENT IN FOCAL THERAPY AND ITS APPLICABILITY TO INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
Y. Matsuoka1, K. Saito2, N. Numao1, H. Tanaka2, M. Inoue1, M. Ito1, S. Yoshida1, M. Yokoyama2, J. Ishioka1, Y. Fujii1, K. Kihara1
1 Tokyo Medical and Dental University Graduate School, Tokyo, Japan
2 Ochanomizu Surugadai Clinic, Tokyo, Japan


PP17 | THE PROSTATE CANCER RISK ASSESSMENT FACILITATES EARLY DIAGNOSIS AND PROPER SELECTION OF LOW- AND INTERMEDIATE RISK PATIENT AS A POTENTIAL CANDIDATES FOR ACTIVE SURVEILLANCE AND FOCAL THERAPY IN BLACK AMERICANS MEN OF HAITIAN DESCENT: A SINGLE CENTER EXPERIENCE
A. Gousse, T. M. Kester, R. R. Kester, J. P. M. Lamour, V. Mouraviev
Bladder Health and Reconstructive Urology, Miramar Memorial Hospital, Miramar, FL, USA

PP18 | THE RETROSPECTIVE RE-EVALUATION OF RESULTS OF SYSTEMATIC PROSTATE BIOPSY AS A SELECTIVE CRITERIA FOR FOCAL THERAPY IN BLACK AMERICANS MEN OF HAITIAN DESCENT
A. Gousse, T. M. Kester, R. R. Kester, J. P. M. Lamour, V. Mouraviev
Bladder Health and Reconstructive Urology, Miramar Memorial Hospital, Miramar, FL, USA

PP19 | THE USE OF MULTIPARAMETRIC MRI OF THE PROSTATE IN MEN PRESENTING WITH SUSPECTED PROSTATE CANCER
V. Otti, C. Miller, R. Thomas, J. S. McGrath
Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom

PP20 | TRANSRECTAL ULTRASOUND VERSUS MAGNETIC RESONANCE IMAGING IN THE ESTIMATION OF PROSTATE VOLUME
S. Davies, W. Lynch
St. George Hospital, Kogarah, Australia

PP21 | TREATMENT PATTERNS FOR PROSTATE CANCER IN A TERTIARY CARE ACADEMIC CENTER IN BUENOS AIRES - ARGENTINA
H. Rios Pita, P. Contreras, L. Blas, M. Mieggi, E. Mondelo, E. Rojas Bilbao
Hospital Alemάn, Buenos Aires, Argentina

PP22 | TWO CASES OF BILATERAL MUCINOUS TUBULAR AND SPINDLE CELL CARCINOMAS
S. Davies1, F. Maclean2
1 University of Sydney, Sydney, Australia
2 Douglass Hanly Moir, Sydney, Australia

PP23 | USE OF GALLIUM-68 TRACERS AND THERANOSTIC POINT OF VIEW (LU-177 COMPOUNDS) IN CLINICAL SETTINGS IN THE UNITED STATES (U.S.) AND THE EUROPE UNION (EU) FOR FUTURE PERSONALIZED MEDICINE: AN OVERVIEW, REGULATIONS, IMAGING FEATURES AND FUTURE PROSPECTIVE
B. Barrios-Lopez1, 2, D. Lumen1, A. Airaksinen1, K. Bergström2, 3
1 Laboratory of Radiochemistry, Faculty of Chemistry, University of Helsinki, Finland
2 Division of Pharmacology and Toxicology, Faculty of Pharmacy, University of Helsinki, Finland
3 HUS Medical Imaging Center, Helsinki University Central Hospital, Finland

PP24 | UTILIZATION OF MULTIPARAMETRIC MRI IN PATIENTS WITH ELEVATED PSA AND PRIOR NEGATIVE TRUS-GUIDED BIOPSIES: CORRELATION WITH IMAGING-GUIDED TARGET BIOPSIES
J. Yu1, A. S. Fulcher1, A. L. Ware1, M. Brooks2, W. C. Behl2, M. A. Turner1, S. G. Winks1, M. B. Grob3, L. Hampton3
1 VCU Medical Center, Dept of Radiology, Richmond, USA
2 VCU School of Medicine, Richmond, USA
3 VCU Medical Center, Dept of Urology, Richmond, USA

PP25 | WITHIN-CORE AND WITHIN-GLAND CANCER LOCALIZATION - IMPLICATIONS ON REAL-LIFE PROSTATE CANCER MANAGEMENT
M. Cohen1, B. Yudkevich2, H. Yodko3, I. Elmalah3
1 Department of Urology, HaEmeq Medical Center, Haifa, Israel
2 Department of Urology, HaEmeq Medical Center, Alufa, Israel
3 Department of Pathology, HaEmeq Medical center, Afula, Israel




PP26
|
ASSESSMENT OF NEEDLE TIP DEFLECTION DURING TRANSRECTAL GUIDED PROSTATE BIOPSY- IMPLICATIONS FOR TARGETED BIOPSIES

D. Halstuch, J. Baniel, R. Ozalvo, S. Tuval, Y. Ber, L. Shavit-Greivink, D. Margel
Rabin Medical Center, Petah Tikva, Israel

PP27 | COMPARING HIFU HEMIABLATION TO ROBOTIC PROSTATECTOMY IN THE MANAGEMENT OF UNILATERAL PROSTATE CANCER: A MATCHED PAIR ANALYSIS
R. van Velthoven, S. Albisinni, F. Aoun, S. Bellucci, I. Biaou, K. Limani, E. Hawaux, A. Peltier
Department of Urology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium

PP28 | COMPARISON OF HEALTH RELATED QUALITY OF LIFE OUTCOMES IN MEN WHO HAD FOCAL CRYOTHERAPY TO THOSE ON ACTIVE SURVEILLANCE
D. J. Habibian, R. Calixte, K. Kosinski, A. E. Katz
Winthrop University Hospital, Mineola, NY 11501, USA

PP29 | DEFLECTION ANALYSIS OF DIFFERENT NEEDLE DESIGNS FOR TRANSPERINEAL PROSTATE BIOPSY AND FOCAL THERAPY
N. Stone1, D. Schechter2, J. Goetz2, M. S. Lucia3, E. E. Smith3, E. D. Crawford3
1 The Icahn School of Medicine at Mount Sinai, New York, USA
2 Vention Medical, Boulder, USA
3 Anschutz University Colorado, Aurora, USA

PP30 | DEVELOPMENT OF CONVECTIVE WATER VAPOR ENERGY FOR TREATING LOCALIZED PROSTATE CANCER: FIRST-IN-MAN EARLY CLINICAL EXPERIENCES
C. Dixon1, C. Cabanas2, R. Rodriguez3, T. Larson4
1 Lenox Hill Hospital, New York, NY, USA 3 University Hospital, Panama City, Panama
2 Hospital Central del IPS, Asuncion, Paraguay 4 Institute of Medical Research, Scottsdale, AZ, USA

PP31 | FEASIBILITY OF TUR AS A MODALITY OF ORGAN PRESERVING STRATEGY in CAP
A. Shtricker, L. Schreiber, A. A. Sidi, A. Tsivian
Departments of Urologic Surgery and Pathology, The Edith Wolfson Medical Center, Holon, Sackler School of Medicine, Tel Aviv University, Israel

PP32 | FIRST 30 FOCAL ONE® PROSTATE FOCAL THERAPY: SHORT TERM EVALUATION
S. Regusci, M. Martins-Favre, C. H. Rochat, G. A. De Boccard, I. Szalay-Quinodoz, S. Rohner
SIPC Swiss International Prostate Center, Geneva, Switzerland

PP33 | FOCAL THERAPY WITH HIGH - INTENSITY FOCUSED ULTRASOUND FOR LOCALIZED PROSTATE CANCER: 3-YEAR FOLLOW-UP
I. Lumpov, A. Amosov, G. Krupinov
I. M. Sechenov First Moscow State Medical University, Moscow, Russia

PP34 |
FOCAL THERAPY WITH HIGH INTENSITY FOCUSED ULTRASOUND IN LOW RISK PROSTATE CANCER
C. Chaussy1, S. Thueroff2
1 Department of Urology, University Regensburg, Regensburg, Germany
2 Department of Urology, Klinikum Harlaching, Munich, Germany

PP35 | HEMI-GLAND BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER
K. Saito, Y. Matsuoka, N. Numao, K. Hayashi, K. Toda, M. Ito, M. Inoue, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Fujii, R. Yoshimura, K. Kihara
Tokyo Medical and Dental University, Tokyo, Japan

PP36 | HIGH INTENSITY FOCUSED ULTRASOUND HEMIABLATION VERSUS MRI GUIDED ‘LESION ONLY’ ABLATION OF PROSTATE CANCER – GENITO-URINARY FUNCTIONAL OUTCOMES AND COMPLICATIONS
A. Sivaraman, R. Sanchez-Salas, E. Barret, E. Espinos Linares, J. I. Perez-Reggeti, M. Galino, F. Rozet, X. Cathelineau
Institut Mutualiste Montsouris, Paris, France

PP37 | INTRAPROSTATIC EFFICACY ANALYSIS OF ABLATHERM HIFU BASED ON OVER 15,000 BIOPSY CORES: IMPLICATION FOR FOCAL THERAPY
S. Thueroff1, C. Chaussy2
1 Department of Urology, Klinikum Harlaching, Munich, Germany
2 Department of Urology, University Regensburg, Regensburg, Germany

PP38 | IS SALVAGE FOCAL CRYOTHERAPY CURATIVE TREATMENT FOR PATIENTS WITH LOCALIZED RECURRENT PROSTATE CANCER?
C. J. Berg, K. E. Kosinski, A. E. Katz
Winthrop University Hospital, Mineola, NY 11501, USA

PP39 | LOCAL RADICAL TUMORABLATION THROUGH COMBINED TRANSURETHRAL RESECTION AND TRANSRECTAL HIGH INTENSITY FOCUSED ULTRASOUND: A VALID THERAPY TO TREAT HIGH RISK PROSTATE CANCER?
C. Chaussy1, S. Thueroff2
1 Department of Urology, University Regensburg, Regensburg, Germany
2 Department of Urology, Klinikum Harlaching, Munich, Germany

PP40 | MINIMALLY INVASIVE SALVAGE PROSTATECTOMY AFTER PRIMARY RADIATION OR ABLATION TREATMENT: COMPLICATIONS, FUNCTIONAL AND LONG-TERM ONCOLOGICAL OUTCOMES
E. Espinos Linares1, R. Sanchez-Salas2, A. Sivaraman2, J. I. Perez-Reggeti3, E. Barret2, M. Galiano2, F. Rozet2, D. Prapotnich2, X. Cathelineau2
1 Hospital Universitario Infanta Sofίa, Madrid, Spain
2 Institute Mutualiste Montsouris, Paris, France
3 Universitari de Bellvitge, Barcelona, Spain

PP41 | MRI-US FUSION GUIDED HIGH-INTENSITY FOCUSED ULTRASOUND WITH FOCAL-ONE® SYSTEM: IMPACT ON PSA, COMPLICATIONS AND GENITO-URINARY FUNCTIONS DURING INITIAL EXPERIENCE
J. I. Perez-Reggeti, R. Sanchez-Salas, E. Espinos Linares, A. Sivaraman, A. Russo, G. Hernandez Palacios, E. Barret, M. Galiano, F. Rozet, N. Cathala, A. Mombet, D. Prapotnich, X. Cathelineau
Institute Mutualiste Montsouris, Paris, France

PP42 | ONCOLOGIC OUTCOMES AFTER HEMIABLATION THERAPY FOR LOCALIZED PROSTATE CANCER
E. Espinos Linares1, E. Barret2, J. I. Perez-Reggeti3, A. Sivaraman2, R. Sanchez-Salas2, M. Galiano2, F. Rozet2, D. Prapotnich2, X. Cathelineau2
1 Hospital Universitario Infanta Sofίa, Madrid, Spain
2 Institute Mutualiste Montsouris, Paris, France
3 Universitari de Bellvitge, Barcelona, Spain

PP43 | PROPENSITY SCORE MATCHED COMPARISON OF PARTIAL TO WHOLE GLAND CRYOTHERAPY FOR INTERMEDIATE-RISK PROSTATE CANCER: AN ANALYSIS OF THE COLD REGISTRY DATA
K. J. Tay1, T. J Polascik1, A. Elshafei2, E. Tsivian1, J. S. Jones2
1 Duke University Medical Center, Durham, NC, USA 2 Cleveland Clinic, Cleveland, Ohio, USA

PP44 | PROSTATE BIOPSY CORE LENGTH CONSISTENCY IN A NEEDLE DESIGNED FOR TRANSPERINEAL BIOPSY AND FOCAL THERAPY
N. Stone1, D. Schechter2, J. Goetz2, M. S. Lucia3, E. E. Smith3, E. D. Crawford3
1 The Icahn School of Medicine at Mount Sinai, New York, USA
2 Vention Medical, Boulder, USA
3 Anschutz University Colorado, Aurora, USA

PP45 | RADIOFREQUENCY ABLATION FOR RENAL TUMORS: A SINGLE CENTER EXPERIENCE
J. Jae Yong1, H. G. Jeon1, B. C. Jeong1, S. I. Seo1, S. S. Jeon1, H. M. Lee1, H. Y. Choi1, B. K. Park2
1 Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

PP46 | RADIOFREQUENCY ABLATION VERSUS PARTIAL NEPHRECTOMY FOR TREATMENT OF RENAL MASSES FOR SMALL BOSNIAK III OR IV CYSTIC RENAL TUMORS
Wan Song , Hakmin Lee, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, and Hyun Moo Lee
Department of Urology Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

PP47 | ROLE OF ENDOCYTIC TRAFFICKING IN LOCAL GENE DELIVERY VIA ELECTROTRANSFECTION
L. D. Cervia, F. Yuan
Duke University, Durham, North Carolina, USA

PP48 | TRANSPERINEAL SATURATION/FUSION BIOPSIES INTEGRATION IN HIFU PROSTATE FOCAL TREATMENT BY FOCAL ONE®
S. Regusci, M. Martins-Favre, C. H. Rochat, G. A. De Boccard, I. Szalay-Quinodoz, S. Rohner
SIPC Swiss International Prostate Center, Geneva, Switzerland

PP49 | TREATMENT WITH FOCAL HIFU IN LOW-INTERMEDIATE RISK LOCALISED PROSTATE CANCER: OUR INITIAL EXPERIENCE
F. Yencilek1, A. T. Ozdemir1, H. Koyuncu Hakan, E. Yencilek2, E. Kocakoc3, H. Luleci4
1 Yeditepe University Medical Faculty, Department of Urology, Istanbul, Turkey
2 Haydarpasa Numune Education and Research Hospital, Department of Radiology, Istanbul, Turkey
3 Yeditepe University Medical Faculty, Department of Radiology, Istanbul, Turkey
4 Medistate Hospital, Department of Urology, Istanbul, Turkey



2013



PP-01
Can optical biopsies accurately diagnose prostate cancer? First-in-human clinical trial data
D.E. Crawford1, E.E. Jasion2, Y. Liu1, J.W. Daily3, R.S. Nash4, P.N. Werahera1, A. Tehrani2
1 University of Colorado, Anschutz Medical Campus, Aurora, CO, USA
2 Precision Biopsy LLC, Boston, MA, USA
3 University of Colorado Boulder, Boulder, CO, USA
4 Centennial Pathologists, Centennia, PC, USA

PP-02
Morphological assessment of anterior lesions on prostate MP-MRI
A. El-Shater Bosaily, H. Ahmed, M. Emberton, C. Allen, M. Arya, S. Punwani, A. Freeman, A. Kirkham
University College London, University College London Hospitals, London, United Kingdom

PP-03
Repeat prostate biopsy after initial benign standard biopsies – Comparison of 3 advanced techniques; MRI/TRUS fusion transperineal, transperineal sector, extensive transrectal prostate biopsies (MD Anderson protocol)
T. Kuru, V. Popeneciu, A. Cantiani, M. Roethke, B. Hadaschik, C. Kastner, S. Pahernik
Heidelberg University Hospital, Heidelberg, Germany

PP-04
Relationship between intra-operative prostatic swelling during HIFU and unsuccessful ablation assessed by contrast MRI and biopsy: Implication for focal HIFU therapy
S. Shoji1, T. Uchida1, M. Nakamoto2, A. Hashimoto1, T. Tomonaga1, H. Kim1, A.L. De Castro Abreu2, S. Leslie2, Y. Sato3, I. Gill2, O. Ukimura2
1 Tokai University Hachioji Hospital, Hachioji, Japan
2 USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
3 Osaka University Graduate School of Medicine, Suita, Japan

PP-05
Improved prostate cancer localization with DCE-MRI dispersion imaging
S. Turco1, K. Kompatsiari1, J.J. de la Rosette2, H. Wijkstra1,2, M. Mischi1
1 Eindhoven University of Technology, Eidhoven, The Netherlands
2 Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

PP-06
Initial experience of 2nd look biopsy in patients on surveillance for positive and/or suspicious for cancer in the 1st look biopsy using image-based 3D mapping biopsy technology
O. Ukimura, A.A. Luis de Castro, M. Nakamoto, S. Shoji, S. Leslie, T. Matsugasumi, M. Desai, M. Aron, I. Gill
University of Southern California, Los Angeles, CA, USA

PP-07
Prostate histoscanning as a tool for decision making
R. Sanchez-Salas1, C. Giedelman1, L. Lunelli1, X. Cathelineau1, P. Macek2, E. Barret1, M. Galiano1, F. Rozet1, Y. Ahallal1, J.M. Gaya1, M. Durand1, L. Mascle1
1 Institut Montsouris, Paris, France 
2 Charles University, Prague, Czech Republic

PP-08
Comparison of diagnostic performance between magnetic resonance imaging guided prostate biopsy and systematic 14-core biopsy including anterior samplings
N. Numao, T. Kijima, Y. Nakanishi, S. Yoshida, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii, K. Kihara
Tokyo Medical and Dental University Graduate School, Tokyo, Japan

PP-09
How accurate is multiparametric Magnetic Resonance Imaging in evaluating prostate cancer volume?
F. Bratan, C. Melodelima, R. Souchon, F. Mège-Lechevallier, O. Rouvière
Department of Urinary and Vascular Imaging, E. Herriot Hospital, Lyon, France

PP-10
Detection of prostate cancer by contrast-ultrasound dispersion imaging
M. Kuenen1, T. Saidov1, C. Heneweer2, H. Wijkstra3, J. de la Rosette3, M. Mischi1
1 Eindhoven University of Technology, Eindhoven, Netherlands
2 University Hospital Schleswig-Holsteein, Kiel, Germany
3 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

PP-11
Complications following prostate biopsy
S. Iyer, H. Rai, S. Upsdell
Department of Urology, Nobles Hospital, Douglas, Isle of Man, United Kingdom

PP-12
Ultrasound-histology registration for validation of prostate cancer imaging techniques
S.G. Schalk1, M. Mischi1, T.A. Saidov1, M. Smeenge2, J.J.C.M.H. de la Rosette2, H. Wijkstra1,2
1 Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
2 Department of Urology, AMC University Hospital, Amsterdam, The Netherlands

PP-13
Rigid and non-rigid prostate image registration of ARFI and MRI image volumes to whole-mount histology
T. Polascik1, E. Kulbacki2, J. Madden2, K. Nightingale3, S. Lipman3, M. Palmeri3, S. Rosenzweig3, K. Garcia-Reyes4, C. Kauffman5, R. Gupta5, A. Lark2, A. Buck2
1 Department of Urology, Duke University Medical Center, Durham, NC, USA
2 Department of Pathology, Duke University Medical Center, Durham, NC, USA
3 Department of Biomedical Engineering, Duke University, Durham, NC, USA
4 Duke University Medical Center, Durham, NC, USA
5 Department of Radiology, Duke University Medical Center, Durham, NC, USA

PP-14
Anterior prostate cancer: Gleason score based on MRI/TRUS elastic image fusion guided prostate biopsy vs prostatectomy
E. Baco1, E. Rud2, L. Vlatkovic3, A. Svindland3, H. B. Eggesbo2
1 Division of Surgery and Cancer Medicine, Department of Urology, Oslo University Hospital, Oslo, Norway
2 Division of Diagnostic and Intervention, Department of Radiology and Nuclear Medicine, Oslo University, Oslo, Norway
3 Division of Diagnostic and Intervention, Department of Pathology, Oslo University, Radiumho, Oslo, Norway

PP-15
WITHDRAWN

PP-16
Value of targeted prostate biopsy using MRI-3DTRUS fusion for first round biopsy in men with normal DRE and PSA <20ng/ml
P. Mozer, P. Conort, E. Comperat, G. Coffin, R. Renard-Penna
Pitié-Salpétrière Hospital, Paris, France

PP-17
Detection of radiorecurrent prostate cancer using diffusion weighted MRI and targeted biopsies
E. Rud1, E. Baco2, D. Klotz3, D. Lien4, H.B. Eggesbø1
1 Department of Radiology, Oslo University Hospital, Oslo, Norway
2 Department of Urology, Oslo University Hospital, Oslo, Norway
3 Department of Pathology, Oslo University Hospital, Oslo, Norway
4 Department of Biostatistics, Oslo University Hospital, Oslo, Norway

PP-18
Preliminary results from an ex-vivo optical coherence tomography of the human prostate after radical prostatectomy
B.G. Muller1, W. van den Bos1, D.M. de Bruin1,2, M.J. Brandt2, D.J. Faber2, M. van de Vijver, M.P. Laguna-Pes1, T.G. van leeuwen2, J.J.M.C.H. de la Rosette1
1 Department of Urology, Academic Medical Center, Amsterdam, The Netherlands
2 Department of Biomedical Engineering & Physics, Academic Medical Center, Amsterdam, The Netherlands

PP-19
Selection of candidates for focal therapy of prostate cancer in unscreened population
A. Govorov, A. Vasyliev, M. Kovylina, E. Prilepskaya, T. Moiseenko, D. Pushkar
MSMSU, Moscow, Russia

PP-20
Repeat biopsy of prior positive sites in men on active surveillance for prostate cancer
S. Natarajan1, G.A. Sonn2, E. Chang2, D.J. Margolis3, M. Macairan2, P. Lieu2, J. Huang4, F.J. Dorey5, R.E. Reiter2, L.S. Marks1,2
1 Center for Advanced Surgical and Interventional Technology, University of California, Los Angeles, CA, USA
2 Department of Urology, University of California, Los Angeles, CA, USA
3 Department of Radiology, University of California, Los Angeles, CA, USA
4 Department of Pathology, University of California, Los Angeles, CA, USA
5 Department of Orthopedic Surgery, University of California, Los Angeles, CA, USA

PP-21
A prospective comparative study of HistoscanningTM and multiparametric 3Tesla MRI for the prediction of cancer foci in men undergoing radical prostatectomy
C. Orczyk1,2, A.B. Rosenkrantz2, J. Melamed2, F.-M. Deng2, J. Wysok2, S.S. Taneja2
1 University Hospital of Caen, Caen, France
2 NYUMC, New York, NY, USA

PP-22
Small-volume unilateral prostate cancer estimation results (SUPER) score to aid candidate selection for focal therapy: Development and validation
M. Tsivian1, S. Freedland1,2, M.R. Abern1, L.L. Bañez1,2, J.C. Presti Jr.3, W.J. Aronson4,5, M.K. Terris6, C.J. Kane7, C.L. Amling8, J.W. Moul1, T.J. Polascik1,2
1 Division of Urologic Surgery, Department of Surgery and the Duke Prostate Center, Duke University Medical Center, Durham, NC, USA
2 Urology Section, Veterans Affairs (VA) Medical Center, Durham, NC, USA
3 Department of Urology, Stanford University Medical Center, and Urology Section, Department of Surgery, VA Medical Center, Palo Alto, CA, USA
4 Urology Section, Department of Surgery, VA Medical Center, Greater Los Angeles, CA, USA
5 Department of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA, USA
6 Urology Section, Department of Surgery, VA Medical Center, Augusta, GA, USA
7 Division of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA, USA
8 Division of Urology, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL; Section of Urology, Department of Surgery, VA Medical Center, Birmingham, AL, USA
 
PP-22a
The Smart-BxTM – Initial experience with a semi-automated prostate biopsy core download system
M. Cohen1, A. Shefler2, S. Patsiansky2, K. Shapira-Schweitzer3, O. Nativ2, J. Bejar2
1 Department of Urology, Emek Medical Center, Afula, Israel
2 Department of Urology, Bnai-Zion Medical Center, Haifa, Israel
3 UC-Care Medical Systems, Yokneam, Israel



PP-23
Start of salvage treatment for persistent positive biopsies after HIFU
R. Sanchez-Salas1, D. Prapotnich1, F. Secin2, E. Barret1, F. Rozet1, M. Galiano1, A. Mombet1, N. Cathala1, X. Cathelineau1
1 Institut Montsouris, Paris, France
2 CEMIC, Buenos Aires, Argentina
 
PP-24
Feasibility study to evaluate the safety and preliminary effectiveness of focal MR-guided focused ultrasound treatment of locally confined low-risk prostate cancer – Initial North American experience
S. Ghai, U. Lindner, T. van der Kwast, E. Hlasney, P. Spensieri, S. McCluskey, M. Haider, W. Kucharczyk, J. Trachtenberg
University Health Network, University of Toronto, Toronto, ON, Canada

PP-25
Nerve sparing HIFU as primary "focalized" treatment for localized prostate cancer: A single center study of 295 men with 7 years of follow up
C. D'Hont, P. Van Erps, M. Sorber, J. Cortvriend, T. Debacker
ZNA Middelheim, Antwerp, Belgium

PP-26
Quadrant-ablation focal therapy of prostate cancer: Candidate selection through a combination of extended biopsy and MRI
Y. Matsuoka1, N. Numao1, K. Saito1, H. Tanaka2, S. Yoshida2, M. Yokoyama1, J. Ishioka1, F. Koga1, H. Masuda1, Y. Fujii1, K. Kihara1
1 Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
2 Department of Radiology, Ochanomizu Surugadai Clinic, Tokyo, Japan

PP-27
WITHDRAWN

PP-28
Hemi-gland brachytherapy for unilateral prostate cancer
K. Saito1, Y. Matsuoka1, N. Numao1, T. Kijima1, S. Yoshida1, M. Yokoyama1, J. Ishioka1, F. Koga1, H. Masuda1, Y. Fujii1, K. Hayashi2, H. Shibuya2, K. Kihara1
1 Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
2 Department of Radiology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

PP-29
MR-guided focal cryoablation of recurrent prostate cancer: How we do it
C.G. Overduin, J.G.R. Bomers, Y. Derya, M.J.P.M. Sedelaar, N.J.T.E. van Lin, S.F.M. Jenniskens, J.J. Fütterer
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

PP-30
“Dynamic” active surveillance; a new strategy to follow patients with low and intermediate risk prostate cancer: Combined results of Phase I/II trial of MR imaging-guided focal laser ablation for low-to-intermediate risk prostate cancer
T. Barrett, M. Sussman, A. Fenster, W. Kucharczyk, J. Trachtenberg, S. Ghai, U. Lindner, M. Haider, O. Raz, S. Davidson, J. Cepek, E. Hlasney, M. Gertner
University Health Network, University of Toronto, Toronto, ON, Canada
 
PP-31
MR-guided focal cryoablation of prostate cancer recurrence following radiotherapy: Short term follow-up
J. Bomers1, M. Sedelaar1, J. Fütterer1, S. Jenniskens1, D. Yakar1, C. Overduin1, H. Vergunst2, E. van Lin1, F. de Lange1, E. Cornel3, J. Barentsz1
1 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2 Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands
3 Cornel Erik, Ziekenhuisgroep Twente, Hengelo, The Netherlands

PP-32
Salvage regional low-dose-rate brachytherapy for local recurrence of prostate cancer after definitive radiotherapy
H. Sasaki, M. Kido, K. Miki, H. Takahashi, M. Aoki, S. Egawa
Jikei University School of Medicine, Tokyo, Japan

PP-33
Irreversible electroporation in the focal treatment of prostate cancer: Initial results
M. Valerio*, L. Dickinson*, H.U. Ahmed, A. Smith, C. Allen, M. Emberton
University College London, London, United Kingdom
*Joint first authors

PP-34
Development of a novel robot for prostate focal therapy and brachytherapy
J.-A. Long, N. Hungr, J.-Y. Giraud, M. Baumann, M. Bolla, J.-J. Rambeaud, J. Troccaz, J.-L. Descotes
Grenoble University Hospital, Grenoble, France

PP-35
MRI-guided focal laser ablation of prostate cancer using a mechatronic needle guidance system: Experience in seven patients
J. Cepek1, U. Lindner2, S. Ghai2, M. Haider2, S.R.H. Davidson2, E. Hlasny2, J. Trachtenberg2, W. Kucharczyk3, A. Fenster1
1 Robarts Research Institute, London, ON, Canada
2 University Health Network, Toronto, ON, Canada
3 Toronto, ON, Canada

PP-36
Salvage HIFU therapy in 5 patients after radical prostatectomy with biopsy confirmed local recurrence
O. Apolikhin, A. Sivkov, N. Keshishev, G. Kovchenko, A. Tsoy
Scientific Research Institute of Urology, Moscow, Russia

PP-37
Tolerance and efficacy of High Intensity Focused Ultrasound (HIFU) focal therapy as primary treatment for localized prostatic carcinoma: Preliminary results
P. Conort, R. Renard-Penna, E. Comperat, S. Charlon, P. Mozer
Pitié-Salpétrière Hospital, Paris, France

PP-38
Precision-targeted dynamic prostate low dose rate brachytherapy
B. Taylor1,2, R. Popert2, M. McGovern2, S. Morris2
1 King's College London, London, United Kingdom
2 Guy's & St Thomas NHS Foundation Trust, London, United Kingdom

PP-39
Denonvillier’s space expansion by hydrogel injection for thermal protection of rectal wall during prostate cryoablation to facilitate extensive freezing beyond the posterior prostatic surface: Cadaver study
A.L. de Castro Abreu, Y. Ma, S. Shoji, S. Leslie, H. Ahmadi, A. Dharmaraja, R. Azhar, M. Alemozaffar, I. Gill, O. Ukimura
USC Institute of Urology, Los Angeles, CA, USA

PP-40
Bilateral focal ablation of prostate tissue using low energy direct current (LEDC): A preclinical canine study
M. Tsivian, T.J. Polascik
Division of Urology, Department of Surgery, Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA

PP-41
Hemi salvage HIFU in unilateral radio-recurrent prostate cancer: A prospective two-centre study
E. Baco1, S. Crouzet2, E. Rud3, O. Rouvière4, H. Tonoli-Catez2, J.-Y. Chapelon5, V. Berge1, A. Gelet2
1 Division of Surgery and Cancer Medicine, Department of Urology, Oslo University Hospital, Aker, Oslo, Norway
2 Hospices Civils de Lyon, Department of Urology and Transplantation Surgery, Edouard Herriot Hospital, Lyon, France
3 Division of Diagnostic and Intervention, Department of Radiology and Nuclear Medicine, Oslo University, Oslo, Norway
4 Hospices Civils de Lyon, Department of Urinary and Vascular Imaging, Edouard Herriot Hospital, Lyon, France
5 Inserm, U1032, LabTau, Lyon, France; Lyon University, Lyon, France

PP-42
Guidance software for MR-guided focal laser thermal therapy of prostate cancer
S.R.H. Davidson1, U. Lindner2, J. Cepek3,4, M. Sussman5, M. Haider5, S. Ghai5, A. Fenster3,4, J. Trachtenberg2
1 Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
2 Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, Canada
3 Robarts Research Institute, London, ON, Canada
4 Biomedical Engineering, Western University, London, ON, Canada
5 Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada



PP-43
Predictors of ablative success of RFA for small renal masses
T. Tailly, T. Van den Broeck, S. Joniau
University Hospitals Leuven, Leuven, Belgium

PP-44
Oncological and functional results of RFA for small renal masses in solitary kidneys. A single-center experience of 35 ablations in 29 patients
T. Van den Broeck, T. Tailly, S. Joniau
Department of Urology, University Hospitals Leuven, Leuven, Belgium

PP-45
Ablation of small renal masses with microwave AMICA-probe. Results of a prospective multicenter phase I-II study
P. Gontero1, G. Berta1, S. Giona1, T. Cai2, B. Frea1, G. Carmignani3, R. Bartoletti4
1 Urology Clinic, University of Turin, ASO City Health and Science of Turin, Turin, Italy
2 Department of Urology, S. Chiara Hospital, Trento, Italy
3 Urology Clinic "Luciano Giuliani", University of Genoa, AOU San Martino Hospital, Genoa, Italy
4 Department of Urology, Hospital Santa Maria Annunziata, Florence, Italy

PP-46
MR imaging-guided percutaneous cryotherapy of renal tumors. Our initial experience in 10 patients
V. Argyropoulos, E.Chatzidarellis, J. Papazoglou, A. Karelis, E. Konstantakis, A. Kostakopoulos
IASO General Hospital, Athens, Greece

PP-47
Radiation exposure associated with dedicated renal mass computer tomography protocol: Impact of patient characteristics
M. Tsivian, M.R. Abern, P. Qi, J. Yoo, P. Evans, C.Y. Kim, M.E. Lipkin, M.N. Ferrandino, T.J. Polascik
Departments of Surgery, Urology and Radiology, Duke Cancer Institute, Durham, NC, USA
 
PP-48
Long-term outcomes of MRI-guided percutaneous cryoablation for Japanese patients with small renal tumors
I. Hiroyuki, S. Hiroshi, M. Kenta, K. Koichi, E. Shin
Jikei University, Tokyo, Japan

PP-49
Radiofrequency ablation of renal tumors. Minimally invasive alternative treatment
B.F. Amir Nicolau, C. Galvez, O. Halawa Gonzalez, V. Rodriguez Del Rosario, C. Fumero Gorrin, J. Portero Navarro, S. Fumero Arteaga, J. Monllor Gisbert
Hospital Universitario Nuestra Senora de Candelaria, Tenerife, Spain

PP-50
The comparative analysis of the changing immune response after laparoscopic radiofrequency ablation and resection of renal cancer
S. Petrov, A. Nosov, E. Samarceva, I. Baldueva
Petrov Research Institute of Oncology, Saint-Petersburg, Russia

PP-51
Kidney cancer treated by radiosurgery
A. Lederman, B. Gilson, G. Qian, L. Cangiane, E. Dimino
Radiosurgery New York, New York, NY, USA

PP-52
A multicenter evaluation of long-term oncological outcome of radiofrequency of kidney tumors
M. Salagierski1, L. Goeman2, W. Marchand3, T. Thailly4, T. Van den Broeck4, I. Garetto5, A. Veltri5, S. Joniau4
1 Medical University of Łódź, Łódź, Poland
2 St-Jan Hospital, Brussels, Belgium
3 H-Hart Hospital, Roeselare, Belgium
4 University Hospitals, Leuven, Belgium
5 Institute of Radiology, University of Torino, Torino, Italy

PP-53
In vivo optical coherence tomography for the evaluation of upper urinary tract urothelial carcinoma: Initial results from a pilot study
M.T.J. Bus1, B.G. Muller1, D.M. de Bruin1,2, D.J. Faber2, M.P. Laguna-Pes1, T.G. van Leeuwen2, T.M. De Reijke1, J.J. de la Rosette1
1 Department of Urology, Academic Medical Center, Amsterdam, The Netherlands
2 Department of Biomedical Engineering & Physics, Academic Medical Center, Amsterdam, The Netherlands

PP-54
Optical biopsy to improve the diagnosis of kidney cancer
P.G.K. Wagstaff1, D.M. de Bruin1,2, P.J. Zondervan1, O.M. van Delden3, T.G. van Leeuwen2, R.J.A. van Moorselaar4, J.J.M.C.H. de la Rosette1, M.P. Laguna Pes1
1 Department of Urology, Academic Medical Centre, Amsterdam, The Netherlands
2 Department of Biomedical Engineering & Physics, Academic Medical Centre, Amsterdam, The Netherlands
3 Department of Radiology, Academic Medical Centre, Amsterdam, The Netherlands
4 Department of Urology, Free University Medical Centre, Amsterdam, The Netherlands



2012



P-01
Small-volume unilateral prostate cancer estimation results (super) score to aid candidate selection for focal therapy: Development and validation
M. Tsivian, S. Freedland, M.R Abern, L.L. Bañez, L. Gerber, J.C. Presti Jr., W.J. Aronson, M.K. Terris, C.J. Kane, C.L. Amling, J.W. Moul, T.J. Polascik (USA)

P-02
Rigid and non-rigid registration of prostate B-mode and ARFI images to MR and whole-mount histology
M.L. Palmeri, C.M.L. Hsu, S.L. Lipman, T.J. Polascik, M.S. Davenport, C. Kauffman, R.T. Gupta, E. Kulbacki, J. Madden, K.R. Nightingale (USA)

P-03
The impact of saturation biopsy in decision making for low risk prostatic carcinoma after prior positive biopsy
R. Sanchez-Salas, N. Miranda, R. Valero, M. Sanchez-Encinas, A. Ouzzane, M. Galiano, F. Rozet, E. Barret, X. Cathelineau (France)

P-04
Magnetic resonance imaging guided transperineal prostate needle biopsy in patients without a rectum
D. Dajani, B. Wood, P. Pinto, A.N. Hoang, C. Pusateri, D. Volkin, N. Yerram, J. Nix, S. Vourganti, B. Turkbey, P.L. Choyke (USA)
 
P-05
Multi-parametric MRI and subsequent MR/ultrasound fusion biopsy increases the detection of anteriorly located prostate cancers
D. Volkin, N. Yerram, B. Turkbey, A. Hoang, J. Nix, J. Kreucker, A. Rastinehad, W.M. Linehan, P. Choyke, B. Wood, P. Pinto (USA)

P-06
Prostatic swelling and shift of intra-prostatic target during HIFU: Implication for targeted focal therapy
S. Shoji, T. Uchida, N. Masahiko, A. Abreu, S. Leslie, Y. Sato, I. Gill, O. Ukimura (USA & Japan)

P-07
Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detects prostate cancer in patients with prior negative TRUS biopsies
S. Vourganti, N. Yerram, J. Nix, D. Volkin, A. Hoang, B. Turkbey, A. Rastinehad, G.N. Gupta, J. Kruecker, W.M. Linehan, P.L. Choyke, B.J. Wood, P.A. Pinto (USA)

P-08
Low suspicion lesions on multiparametric magnetic resonance imaging do not correlate with high risk prostate cancer
N. Yerram, D. Volkin, B. Turkbey, J. Nix, A. Hoang, S. Vourganti, G.N. Gupta, W.M. Linehan, P.L. Choyke, B.J. Wood, P.A. Pinto (USA)

P-09
Value of targeted biopsy in detecting prostate cancer using an office-based MR-US fusion device
G.A. Sonn, S. Natarajan, D.J.A. Margolis, M. Macairan, P. Lieu, J. Huang, F.J. Dorey, L.S. Marks (USA)

P-10
Targeted prostatic biopsy based on multiparametric magnetic resonance imaging to select candidates for focal therapy of prostate cancer
K. Kamoi, K. Okihara, T. Iwata, F. Hongo, O. Ukimura, A. Kawauchi, T. Miki (Japan & USA)

P-11
High diagnostic yield achieved by targeting multiparametric magnetic resonance imaging-suspicious lesion using MRI/Ultrasound fusion guided prostate biopsy
K. Kamoi, K. Okihara, T. Iwata, F. Hongo, T. Ueda, A. Kawauchi, T. Miki (Japan)

P-12
Image fusion of the preoperative biopsy-proven 3D cancer model and the intraoperative 3D cryolesion: Assessment of therapeutic adequacy in lesion-targeted cryotherapy for prostate cancer
M. Nakamoto, O. Ukimura, N. Fukuda, S. Shoji, A.L.C. Abreu, S. Leslie, Y. Sato, I.S. Gill (USA, Japan)

P-13
Can multiparametric MRI accurately detect local prostate cancer recurrence in patients treated with radiotherapy, before focal salvage therapy?
M.A. Alazeez, H. Ahmed, E. Anastasiadis, M. Arya, A. Freeman, C. Allen, A. Kirkham, M. Emberton (United Kingdom)

P-14
Approaches for overcoming challenges of MRI-guided biopsy of prostate
J. Yu, A.S. Fulcher, M.A. Turner, C. Cockrell (USA)

P-15
Diagnosis of anterior prostate cancer using MRI/TRUS real time soft image fusion
E. Baco, E. Rud, A. Svindland, H.B. Eggesbø (Norway)

P-16
Comparison between systematic and MRI targeted prostate biopsy for patient with no history of prostate cancer attending a first round of trans-rectal ultrasound biopsy procedure
P. Mozer, G. Coffin, G. Chevreau, R. Renard-Penna, E. Compérat, M.-A. Vitrani, C. Torterotot, P. Conort, M.-O. Bitker (France)

P-17
Is a high strength (3Tesla) MRI scan necessary for the detection and characterisation of prostate cancer?
N.L. Robertson, C.M. Moore, M. Emberton (United Kingdom)

P-18
MAPPED - Prevalence of MRI detectable lesions in low-intermediate risk prostate cancer
Nicola L. Robertson, Caroline M. Moore, Mark Emberton (United Kingdom)

P-19
NADiA ProsVue: A prognostic test for identifying men at a reduced risk for prostate cancer recurrence following radical prostatectomy
J. Moul, R. Lance, J. Alter, M. Sarno, J. McDermed (USA)    

 


P-20
Morbidity of focal therapy in the treatment of localized prostate cancer
R. Sanchez-Salas, E. Barret, A. Ouzzane, R. Valero, M. Sanchez-Encinas, F. Rozet, M. Galiano, D. Prapotnich, X. Cathelineau (France)

P-21
Focal therapy of prostate cancer: Initial experience with cryotherapy
R. Sanchez-Salas, E. Barret, M. Galiano, R. Valero, M. Sanchez-Encinas, N. Miranda, F. Rozet, D. Prapotnich, X. Cathelineau (France)

P-22
Comparative evaluation of acute retention of urine in groups of patients with prostate cancer treated with high power and low power brachytherapy
A.U. Pavlov, I.A. Albitski, A.D. Tsibulski, K.N. Milenin, A.V. Shestakov (Russia)

P-23
Medium term outcomes following primary focal therapy using HIFU for localised prostate cancer
L. Dickinson, H. Ahmed, N. McCartan, A. Freeman, A. Kirkham, C. Allen, R. Hindley, M. Emberton (United Kingdom)

P-24
MRI guided prostate cancer focal ablation using HIFU by means of image to image registration
L. Dickinson, Y. Hu, H. Ahmed, C. Allen, A. Kirkham, M. Emberton, D. Barratt (United Kingdom)

P-25
Salvage cryotherapy of the prostate: Long-term clinical, functional, and biochemical outcomes in a large cohort at a tertiary referral center
S. Wenske, A. E. Katz (USA)

P-26
Third generation total cryoablation as primary treatment for organ confined prostate cancer
H. Riemenschneider, E. Hong (USA)

P-27
Magnetic resonance guided intra-urethral high intensity focused ultrasound treatment of prostate tissue in preclinical model
N. Yerram, A. Hoang, A. Partanen, D. Volkin, H. Trivedi, J. Nix, B. Turkbey, M. Dreher, M. Bernardo, D. Haines, W.M. Linehan, P. Choyke, B. Wood, A. Venkatesan, P.A. Pinto (USA)

P-28
Efficacy of low temperature-sensitive liposome encapsulated docetaxel compared to free docetaxel in a xenograft murine model of prostate cancer
A. Ranjan, D. Volkin, N. Yeram, S. Chokshi, C.J. Benjamin, A. Negussie, P.H. Chung, M.R. Dreher, W.M. Linehan, B.J. Wood, P.A. Pinto (USA)

P-29
Histotripsy of ACE-1 implanted prostate tumor: Focal therapy in a canine model
G.R. Schade, J. Keller, K. Ives, X. Cheng, T.J. Rosol, E. Keller, W.W. Roberts (USA)

P-30
The focal laser effects of treatment during interstitial laser coagulation in patients with prostate cancer
O. Teodorovich, A. Teplov, A. Bogoslavskiy, S. Naryshkin, G. Borisenko, Y. Andreeva, E. Rasshupkina, D. Kochiev (Russia)

P-31
Focal radio-frequency ablation for low-risk, focal prostate cancer: Challenges and technique
J.M. Pow-Sang, M. Biagioli, E. Outwater, S. Dickinson, S. Rao (USA)

P-32
Salvage focal vs salvage total cryoablation for radio-recurrent prostate cancer: 7 years experience
A.L. de Castro Abreu, S. Leslie, S. Sohji, P. Silverman, I. Gill, D. Bahn, O. Ukimura (USA)
 
P-33
Prospective phase I trial of differential dose prostate brachytherapy guided by cancer-specific tissue-type imaging (TTI) and ultrasound spectrum analysis (USA): Preliminary dosimetric and clinical results
R. Ennis, F. Trichter, A. Jain, D. Goltz, J. Ostenson, E. Feleppa (USA)

P-34
Hemi salvage HIFU in patients with radiorecurrent prostate cancer
E. Baco, S. Crouzet, E. Rud, O. Rouviere, J.-Y. Chapelon, V. Berge, A. Gelet (Norway & France)

P-35
Delayed radical prostatectomy in intermediate-risk prostate cancer is associated with biochemical recurrence: Results from the SEARCH Database
A. Michael, A. William, T. Martha, K. Christopher, P. Joseph, A. Christopher, F. Stephen

P-36
Focal treatment of prostate cancer with HIFU
S. Crouzet, A. Villers, P. Rischmann, G. Pasticier, D. Hevallier, O. Rouviere, A. Gelet (France)

P-37
Preliminary results of a phase I trial using magnetic resonance-guided focused ultrasound surgery (MRgFUS) for  the treatment of patients with locally-confined low-risk prostate cancer
A. Nosov, C. Cheng, S. Kanaev, G. Gafton, V. Turkevich, A. Vorobiev (Russia & Singapore)



K-01
Renal mass anatomical characteristics and perioperative outcomes of laparoscopic partial nephrectomy: A critical analysis
M. Tsivian, S. Ulusoy, M.R. Abern, A. Wandel, A.A. Sidi, A. Tsivian (USA & Israel)

K-02
Impact of probe angulation on cryoablation zone geometry
Jun Yoo, Joshua Bryant, Charles Kim, Rendon Nelson (USA)

K-03
Renal function outcomes in patients with reduced nephron mass undergoing percutaneous renal cryoablation
D. Sopko, M. Tsivian, M. Suberlack, C.Y. Kim, T.J. Polascik, R.C. Nelson (USA)

K-04
Nd:Yag laser focal effect of localized kidney tumor
S. Naryshkin, O. Teodorovich, G. Borisenko, E. Rasshupkina, A. Ryazancew, D. Kurochkin, D. Kochiev (Russia)

K-05
Nd:YAG intersticial laser coagulation in vivo: Histipathologic analysis of the renal parenchima in different times after effect
E.V. Rasshchupkina, O.V. Teodorovich, G.G. Borisenco, S.A. Naryshkin, D.G. Kochiev (Russia)

K-06
7-year experiences with radiofrequency ablation for small renal masses
F. Vandercruysse, T. Meert, L. De Wever, F. Claus, R. Oyen, H. Van Poppel, S. Joniau (Belgium)

K-07
Zero-ischemia robotic partial nephrectomy: Striving for the trifecta
S. Leslie, M.M. Desai, I.S. Gill, A.L. de Castro Abreu, D.J. Lee, A.K. Berger, A.C. Goh, M. Patil, P.-M. Lewandowski, O. Ukimura, M. Aron (USA)

K-08
Modern hemostatic dressings improve the surgical procedure in murine kidney melanoma and renal cell adenocarcinoma animal models
M. Nowacki, A. Jundzill, M. Bieniek, T. Kowalczyk, S.L. Habib, T. Drewa (Poland & USA)

K-09
Anthropometric Renal Alterations between Supine and Prone Positions in Percutaneous Renal Ablation for Renal Cortical Neoplasms
A. Lusch, S. Fujimoto, J. Graversen, L.K. Findeiss, R. Clayman, J. Landman (USA)

K-10
Radiation exposure in patients undergoing nephron-sparing treatment for small renal masses: Scenario - based estimation
Matvey Tsivian, Michael R. Abern, Mitchell Bassett, Charles Y. Kim, Thomas J Polascik, Michael N Ferrandino (USA)

K-11
Radiation exposure in nephron sparing management of small renal masses: Single center experience
Tsivian M, Bassett M, Abern MR, Kim CY, Polascik TJ, Ferrandino MN, (USA)

 


News